Matthew Kyle Labriola, MD

Assistant Professor of Medicine
Email address matthew.labriola@duke.edu

Basics

College/University
Notre Dame

Medical School
Georgetown

Residency
Duke University

Education and Training

  • Chief Medical Resident, Internal Medicine, Duke University, 2020 - 2021
  • Fellowship, Medical Oncology, Duke University, 2019 - 2020
  • Residency, Internal Medicine, Duke University, 2016 - 2019
  • M.D.C.M., Georgetown University School of Medicine, 2016
  • M.D., Georgetown University School of Medicine, 2016

Publications

Labriola, Matthew K., and Daniel J. George. “Setting a new standard for long-term survival in metastatic kidney cancer.” Cancer 128, no. 11 (June 1, 2022): 2058–60. https://doi.org/10.1002/cncr.34177.

PMID
35383907
Full Text

Koshkin, Vadim S., Vaibhav G. Patel, Alicia Ali, Mehmet A. Bilen, Deepak Ravindranathan, Joseph J. Park, Olesia Kellezi, et al. “PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.” Prostate Cancer Prostatic Dis, August 6, 2021. https://doi.org/10.1038/s41391-021-00433-1.

PMID
34363009
Full Text

Labriola, Matthew K., Saad Atiq, Nathan Hirshman, and Rhonda L. Bitting. “Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.” Prostate Cancer Prostatic Dis 24, no. 2 (June 2021): 301–9. https://doi.org/10.1038/s41391-020-00299-9.

PMID
33168966
Full Text

Brown, Landon C., Matthew D. Tucker, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew K. Labriola, et al. “LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.” J Immunother Cancer 9, no. 3 (March 2021). https://doi.org/10.1136/jitc-2020-001792.

PMID
33653800
Full Text

Labriola, Matthew, and Daniel J. George. “Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations.” American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 41 (March 2021): 1–5. https://doi.org/10.1200/edbk_319899.

PMID
33929878
Full Text

Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.

PMID
32482566
Full Text

Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.

PMID
32923131
Full Text

Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Labriola, Matthew Kyle, Jason Zhu, Rajan T. Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.

PMID
32221016
Full Text

Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.

PMID
30858035
Full Text

Pages